Denali Therapeutics Inc (DNLI) Stock Analysis
Verdict: WATCH (do not buy)
AVLAYAH commercialization validates the TV platform and $1.1B cash funds a 33-month runway — swing risk lies in mid-stage trial execution.
Investment score: 51/100
Analysis as of
Is Denali Therapeutics Inc stock worth reviewing? AI model thesis
The model assesses DNLI as a HOLD. $1.10B in pro-forma liquidity and FDA approval of AVLAYAH ($3.60M Q2 2026 sales) prove the TV blood-brain barrier platform works, but mid-stage pipeline setbacks (BIIB122 Parkinson's failure) require technical stabilization around $16.50 support before adding capital.
7-factor investment score
- Valuation: 42/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 38/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 82/100 (weight 10%)
- Risk-Adjusted Return: 52/100 (weight 15%)
Denali Therapeutics Inc opportunities and risks
What speaks for DNLI
- Commercial Validation of TransportVehicle (TV) Platform
What speaks against DNLI
- Clinical Pipeline Binary Failure Risk (Top Risk)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| DNLI | n/a | 873.0x | n/a | -61.0% | -14191.2% | -13.9% |
| DYN | n/a | 0.0x | n/a | 0.0% | 0.0% | -15.6% |
| RCUS | n/a | 27.3x | n/a | 94.0% | -386.3% | -14.9% |
| ARQT | 115.4x | 6.9x | 74.0x | 91.1% | 6.1% | 1.2% |
| VCYT | 27.9x | 5.7x | 22.7x | 72.1% | 20.4% | 5.2% |
| PURR | 20.9x | 193.1x | n/a | 100.0% | 3358.6% | -1.0% |
| Peer median | 20.9x | 6.9x | n/a | 91.1% | 6.1% | -1.0% |
Frequently asked questions about Denali Therapeutics Inc (DNLI)
Is DNLI stock a good investment?
The cached TradeMates AI model rates Denali Therapeutics Inc as WATCH (do not buy) with an investment score of 51/100. The model assesses DNLI as a HOLD. $1.10B in pro-forma liquidity and FDA approval of AVLAYAH ($3.60M Q2 2026 sales) prove the TV blood-brain barrier platform works, but mid-stage pipeline setbacks (BIIB122 Parkinson's failure) require technical stabilization around $16.50 support before adding capital. This is algorithmic model output, not personal investment advice.
Is DNLI stock a buy?
The TradeMates model verdict for DNLI is WATCH (do not buy) with an investment score of 51/100. Treat this as a model signal to review, not a personal buy recommendation.